What's Happening?
ImmunityBio, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for ANKTIVA in combination with Bacillus Calmette-Guerin (BCG) for treating patients with BCG-unresponsive
non-muscle invasive bladder cancer (NMIBC) with papillary disease. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of January 6, 2027. This decision follows a recent FDA workshop where experts discussed the biological similarities between carcinoma in situ (CIS) and papillary disease, supporting the potential expansion of ANKTIVA's indication. The application is backed by data from the QUILT 3.032 Phase 2/3 trial, which showed promising results in terms of disease-free survival and bladder preservation.
Why It's Important?
The FDA's acceptance of the sBLA for review is a significant step towards potentially expanding treatment options for patients with high-grade BCG-unresponsive NMIBC. Currently, these patients face limited options, often leading to radical cystectomy, which carries high morbidity and mortality risks. If approved, ANKTIVA plus BCG could offer a bladder-sparing alternative, improving quality of life and reducing the risk of disease progression. This development could also enhance ImmunityBio's market position in the immunotherapy landscape, providing a new avenue for treating a larger segment of the bladder cancer population.
What's Next?
The FDA will review the scientific data supporting the sBLA, focusing on the similarities between CIS and papillary disease. If the application is approved, it would expand the current indication for ANKTIVA, allowing more patients access to this treatment. ImmunityBio will continue to engage with the FDA during the review process, aiming to address any concerns and facilitate approval. The outcome of this review could influence treatment guidelines and insurance reimbursement policies, potentially making ANKTIVA a standard care option for NMIBC.
